<div>
  <p>
  </p>
  <ul>
    <li>
      <p>
        ​​Massachusetts-based AI biotechnology company Nimbus Therapeutics and drug discovery company Anagenex have entered a research partnership to discover small-molecule drugs for various complex targets.
      </p>
    </li>
    <li>
      <p>
        As part of the agreement, Anagenex will receive an upfront payment (amount undisclosed) and potential milestone payments. It will also be eligible for an option from Nimbus for each program in the collaboration.
      </p>
    </li>
    <li>
      <p>
        The collaboration will leverage Anagenex's AI-driven parallel biochemistry platform to generate a vast amount of data points for each of Nimbus' nominated targets. The generated data will then be used to train Anagenex&rsquo;s AI models to design target-specific compounds, potentially identifying potent candidates for new medicines.&nbsp;
      </p>
    </li>
  </ul>
  <p>
  </p>
</div>


<div>
  <p>
    <a href="https://www.businesswire.com/news/home/20231218468677/en/Anagenex-and-Nimbus-Announce-a-Multi-Target-Collaboration-to-Discover-Small-Molecule-Therapeutics-for-Multiple-Indications">
      Press release
    </a>
  </p>
  <p>
    <a href="https://aithority.com/machine-learning/anagenex-and-nimbus-announce-a-multi-target-collaboration-to-discover-small-molecule-therapeutics-for-multiple-indications/">
      AIthority
    </a>
  </p>
  <p>
  </p>
</div>


AI Drug Discovery

PROMINENT_CATEGORY

<div>
 <p>Nimbus Therapeutics and Anagenex have announced a research partnership aimed at discovering small-molecule drugs for complex targets. Anagenex will get an upfront payment and potential milestone payments, and be eligible for an option from Nimbus for each program in the collaboration. The partnership will utilise Anagenex's AI-driven parallel biochemistry platform to generate large amounts of data for Nimbus' nominated targets. The data will be used to train Anagenex’s AI models to design target-specific compounds, potentially identifying candidates for new medicines.</p>
</div>

Nimbus Therapeutics and Anagenex partner to discover small-molecule drugs

Nimbus Therapeutics has raised $210 million in a private funding round led by new investor GV (Google Ventures) and existing investors SR One and Atlas Venture. The funds will be used to advance the company's pipeline of drugs for various disorders, including ongoing trials of its hematopoietic progenitor kinase 1 inhibitor. Additionally, the company plans to target Werner syndrome helicase and an undisclosed immune target, as well as develop therapies for metabolic disorders through a partnership with Eli Lilly. This funding round follows the company's sale of Nimbus Lakshmi and its TYK2 program to Takeda Pharmaceuticals for $6 billion in February 2023.

All Updates

Nimbus Therapeutics and Anagenex partner to discover small-molecule drugs

Nimbus Therapeutics raises USD 210 million in private financing round

Takeda acquires Nimbus Therapeutics’s subsidiary; pays USD 4 billion upfront

Nimbus Therapeutics closes USD 125 million private financing round

Nimbus Therapeutics closes USD 125 million private financing round

Nimbus Therapeutics closes USD 105 million private financing round